Automate Your Wheel Strategy on VNRX
With Tiblio's Option Bot, you can configure your own wheel strategy including VNRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VNRX
- Rev/Share 0.0136
- Book/Share -0.215
- PB -4.0375
- Debt/Equity -0.0885
- CurrentRatio 0.3982
- ROIC -13.5336
- MktCap 89423964.0
- FreeCF/Share -0.229
- PFCF -4.0452
- PE -3.4879
- Debt/Assets 0.2156
- DivYield 0
- ROE 1.0801
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | VNRX | H.C. Wainwright | -- | Buy | -- | $2.5 | April 8, 2025 |
News
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
Published: June 04, 2025 by: PRNewsWire
Sentiment: Neutral
HENDERSON, Nevada , June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia. The two presentations feature results from two clinical studies conducted by Dr Masahiko Sato, DVM, PhD, DACVIM (SAIM), DAiCVIM (IM) in conjunction with FujiFilm Vet Systems.
Read More
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev. , May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research.
Read More
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update
Published: May 12, 2025 by: PRNewsWire
Sentiment: Neutral
Conference call to take place on Friday, May 16 at 8:30 a.m. U.S Eastern Time Henderson, Nev.
Read More
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral
HENDERSON, Nev. , May 7, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that Chief Commercial Officer, Gael Forterre, has issued a commercial update on Volition's Nu.Q® NETs product.
Read More
VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets
Published: April 29, 2025 by: PRNewsWire
Sentiment: Neutral
HENDERSON, Nev. , April 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that President and Group Chief Executive Officer, Cameron Reynolds, has issued a Shareholder Letter providing a business update.
Read More
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
HENDERSON, Nev. , March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on Wednesday, April 9, 2025, at 10:00 AM ET, featuring Volition's Gael Forterre, Chief Commercial Officer, Dr. Andrew Retter, Chief Medical Officer and Dr. Jake Micallef, Chief Scientific Officer.
Read More
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral
Up to $2.3 million up front with up to an additional $1.1 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev. , March 26, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announces today that it has entered into definitive agreements for the purchase and sale of (i) 2,363,636 shares of its common stock to certain directors, executive officers, and certain existing stockholders of the Company (collectively, the "Insiders") at an offering price of $0.55 per share, and (ii) 1,739,087 shares of its …
Read More
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
"Lung Cancer: Hope of a Brighter Tomorrow" illustrates how Nu.Q® Cancer Test aims to transform the diagnosis, treatment and monitoring in the $4 billion lung cancer market1 HENDERSON, Nev. , March 20, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of Volition's new lung cancer primer, "Lung Cancer: Hope of a Brighter Tomorrow.
Read More
About VolitionRx Limited (VNRX)
- IPO Date 2012-03-02
- Website https://www.volition.com
- Industry Medical - Diagnostics & Research
- CEO Cameron Reynolds MBA
- Employees 85